In a video from The Economist, Organovo co-founder Andras Forgacs discusses bioprinting and its significance to the pharmaceutical industry.
"Tissue engineering...is an emerging field that combines engineering and life sciences to create functional, biological structures that can restore and improve tissue function. Examples include bladders, trachhea, and blood vessels. And if you look at it, printing as a technology has also gone through a revolution. While it's been around for hundreds of years, in the last couple decades it's gained a new dimension. It can now print layer by layer, in materials ranging from plastic to metal to concrete to chocolate, from the smallest scales to the largest. If we take 3D printing and we combine it with biology, we have bioprinting, where the building blocks are cell aggregates - what we call bio ink particles - that are composed of thousands of cells that can fuse together into different shapes."
View the video here.